Bill
SB 477
relative to increasing transparency in the 340B Drug Pricing Program.
2026 Regular Session
Introduced by Keith Ammon and 8 co-sponsors
The bill would eliminate prior authorization and step-therapy requirements for a broad set of drugs, including GLP-1s, to speed timely access but may raise state program costs.
Refer to Interim Study, MA, VV; 03/05/2026; SJ 5